ASKA Pharmaceutical Holdings Co., Ltd.
TTSE:48862,029.00
JPY
+4.00
(+0.20%)
ISIN
JP3119660003
Return %
Stock
S&P 500
1Y
-7.73
14.20
3Y
18.17
81.12
5Y
104.33
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Tomohito Nagao
- Full Time Employees
- 1,611
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 5-1, Shibaura 2-Chome Tokyo TY Japan 108-8532
- IPO Date
- Apr 1, 2021
- Website
- aska-pharma-hd.co.jp
- Similar Companies
- Business
- ASKA Pharmaceutical Holdings Co., Ltd. ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T) serves as the holding company for the ASKA Pharmaceutical Group, which engages primarily in the research, development, manufacturing, marketing, and import/export of pharmaceutical products focused on endocrinology, obstetrics and gynecology, urology, and internal medicine; the company also produces and sells veterinary medicines, quasi-drugs, health foods, and medical devices through subsidiaries including ASKA Pharmaceutical Co., Ltd., ASKA Animal Health Co., Ltd., and ASKA Pharma Medical Co., Ltd. Key products encompass hormone therapies such as THYRADIN for hypothyroidism, LEUPRORELIN ACETATE FOR INJECTION KIT “ASKA” for endometriosis, uterine fibroids, and prostate cancer, RELUMINA tablets for uterine fibroids and endometriosis, oral contraceptives including Slinda 28 Tablets, ANGE, and NORLEVO TABLET as an emergency contraceptive, dysmenorrhea treatments like FREWELL Combination Tablets “ASKA” and DroEthi Combination Tablet “ASKA”, infertility agents such as LUTEUM VAGINAL SUPPOSITORIES, antihypertensives like CANDESARTAN TABLETS “ASKA”, hyperlipidemic agents including LIPIDIL capsules and tablets, benign prostatic hyperplasia treatments such as PROSTAL TABLETS, gastritis agents like ALTAT CAPSULES, hepatic encephalopathy treatments including RIFXIMA TABLETS, and antithyroid agents such as MERCAZOLE TABLETS, MERCAZOLE Injection, and PROPACIL TABLETS; additional offerings include uterine contraction preventives like Magsent Injection and IV MAGNESOL. The group operates manufacturing facilities including the Iwaki Factory in Fukushima and the Shonan Research Center, provides clinical testing services, and maintains international presence through representative offices in London and Frankfurt, an equity affiliate NeoASKApharma Private Limited in India, and operations targeting Southeast Asia; it serves healthcare providers, primarily in Japan with expanding efforts in women's health via initiatives like Mint + Health Lab and femtech advancements. Founded in 1920 as Teikoku Hormone Research Institute in Yokohama, Japan, with headquarters in Tokyo, the company underwent a major reorganization in April 2021 with the establishment of ASKA Pharmaceutical Holdings Co., Ltd. Recent developments include the February 2025 consolidation of Vietnamese Ha Tay Pharmaceutical Joint Stock Company (Hataphar) as a subsidiary to bolster overseas growth under its medium-term management plan aiming for total healthcare expansion; a April 2025 strategic partnership via minority stake acquisition in Philippines-based FTS Ambrose Holdings Inc., parent of MedChoice Pharma; expanded license agreement with Spain's Insud Pharma for exclusive rights to a new women's health product in Japan; June 2025 launch of oral contraceptive Slinda 28 Tablets; November 2025 joint research agreement with PPMX for new antibody drugs; January 2025 collaborations with SUSMED on digital therapeutics for PMS/PMDD and Veneno Technologies for ion channel therapeutics; and July 2025 opening of a ZEB-certified community center “arca” at Iwaki Factory.